Ehrlich tumor inhibition using doxorubicin containing liposomes.

Area of Science:

• Oncology
• Nanomedicine
• Pharmacology

Background:

• Ehrlich ascites carcinoma is a common model for studying tumor growth and anti-cancer drug efficacy.
• Doxorubicin (DOX) is a potent chemotherapeutic agent with limitations in its free form, including toxicity and efficacy.
• Liposomal drug delivery systems offer potential for improved therapeutic outcomes by altering drug pharmacokinetics and biodistribution.

Purpose of the Study:

• To evaluate the anti-tumor efficacy of doxorubicin (DOX) encapsulated in liposomes compared to free DOX in a murine Ehrlich tumor model.
• To investigate the impact of liposomal formulation on drug delivery, tumor growth inhibition, and histopathological changes.

Main Methods:

• Ehrlich tumors were established in female balb mice via subcutaneous injection of Ehrlich ascites carcinoma cells.
• Mice were treated with saline, free doxorubicin (DOX), or DOX encapsulated in liposomes (DMPC/CHOL/DPPG/PEG-PE).
• Tumor growth inhibition, cytotoxicity (IC50), and histopathological features including necrosis percentage were assessed.

Main Results:

• Liposomal DOX exhibited a higher IC50, indicating greater cytotoxicity than free DOX.
• All DOX formulations inhibited tumor growth compared to saline, with liposomal DOX showing more pronounced inhibition.
• Histopathological analysis revealed significantly higher tumor necrosis (up to 70%) in mice treated with liposomal DOX compared to saline (12%).

Conclusions:

• Liposomal doxorubicin formulation enhances anti-tumor activity against Ehrlich tumors.
• The liposomal formulation facilitates efficient drug delivery into tumor cells, potentially via endocytosis or passive diffusion.
• This improved delivery leads to a higher concentration of DOX in tumor cells, enhancing therapeutic index and anti-tumor efficacy.